Hyperkalemia
Hyperkalemia is defined as a blood potassium level higher than 5.5 mmol/L, and severe hyperkalemia is defined as a level greater than 7.0 mmol/L. Hyperkalemia often causes sudden cardiac arrest with few or no symptoms, so it should be detected and treated early.
-
Site of disease:
Blood vessels whole body -
Infectious :
Not contagious -
Frequent population:
No special disease group -
Related symptoms:
Stomach ache irritability nausea confusion suffocation -
Concurrent disease:
Related Drugs
Mexiletine Hydrochloride Tablets
Indication: This product is suitable for chronic ventricular arrhythmias, including ventricular premature beats and ventricular tachycardia.
Sodium Polystyrene Sulfonate Powder
Indication: Potassium-lowering drug. Used for hyperkalemia in acute and chronic renal insufficiency.
Calcium Polystyrene Sulfonate Powder
Indication: Potassium-lowering drugs are mainly used to prevent and treat hyperkalemia in patients with acute and chronic renal insufficiency and renal failure.
LOKELMA- sodium zirconium cyclosilicate_powder, for suspension
Indication: LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12. 2) and Clinical Studies (14) LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults. ( 1 Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
Manufacturer:
AstraZeneca Pharmaceuticals LP
SODIUM POLYSTYRENE SULFONATE- sodium polystyrene sulfonate_powder, for suspension
Indication: Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia. Limitation of Use: Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12. 2)] Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia (1) Limitation of Use: Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action (1).
Manufacturer:
ATLANTIC BIOLOGICALS CORP.
Related Ingredients
-
1-(2,6-Dimethylphenoxy)-2-propanamine list
31828-71-4 -
TROVAFLOXACIN list
147059-72-1